Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a ...

NEW YORK-- ( BUSINESS WIRE )--Hess Corporation (NYSE: HES) announced today that John Hess, Chief Executive Officer, will ...

On Thursday, Wolfe Research exhibited confidence in NVIDIA (NASDAQ:NVDA) shares, increasing the tech giant's price target to $180 from the previous $150. The firm maintains an Outperform rating on ...

On Wednesday, Wolfe Research increased its price target for Lowe's Companies Inc. (NYSE: NYSE:LOW) shares, setting the new goal at $308.00, up from the previous target of $267.00. The firm has ...

On Monday, TransUnion (TRU) stock saw a modest uptick, ending the day at $96.93 which represents a slight increase of $1.27 or 1.33% from the prior close of $95.66. The stock opened at $95.91 and ...

will participate in a Keynote Fireside Chat at the Wolfe Research Oil & Gas Conference Wednesday, November 20 at 7:50 a.m. Eastern Time. A live audio webcast and a replay of the discussion will be ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Wolfe Research downgraded Matson (MATX) to Peer Perform from Outperform. The firm cites valuation for the downgrade. Matson has materially ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

Wolfe projects a positive outlook for Pharma & Large-Cap Biotech stocks despite potential policy changes as part of Make America Healthy Again movement. Read more here.